The capacity of Pyrazinamide (PZA) to prevent the selection of Rifampicin (RMP) resistant mutants was tested by the intravenous innoculation of 160 mice with 2 x 106 c.f.u. of M. tuberculosis, and two weeks later, the treatment of the mice either with 10 mg/kg/day RMP alone or with RMP + PZA 150 mg/kg/day. After three months of treatment, lungs and spleen were culture positive in respectively 95% and 90% of the mice treated with RMP alone and in 37% and 24% of the mice treated by RMP + PZA (p < 10-5). The strains isolated from lungs and spleen were resistant to Rifampicin in respectively 87% and 75% of the mice treated with RMP alone and in none of those treated with RMP + PZA.
|Translated title of the contribution||The prevention of rifampicin resistance with pyrazinamide|
|Number of pages||4|
|Journal||Revue des maladies respiratoires|
|State||Published - Jan 1 1985|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine